Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
about
Radiotherapy for Colorectal Cancer: Current Standards and Future PerspectivesSystematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer.A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1)The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancerIdentification of Predictive Markers for Response to Neoadjuvant Chemoradiation in Rectal Carcinomas by Proteomic Isotope Coded Protein Label (ICPL) Analysis.Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysisPatients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure ratePathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer.Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer.A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy.Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.SEOM Clinical Guideline of localized rectal cancer (2016).Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience.Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer.The clinicopathologic relevance and prognostic value of tumor deposits and the applicability of N1c category in rectal cancer with preoperative radiotherapyOn a prolonged interval between rectal cancer (chemo)radiotherapy and surgery.Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis.Optimal therapy for resectable rectal cancer.Update on advances and controversy in rectal cancer treatment.Current topics in the multimodality treatment of locally advanced rectal cancer.N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting.Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.Patient-centered outcomes to decide treatment strategy for patients with low rectal cancer.[Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer].[Time interval between neoadjuvant radiochemotherapy and surgery in rectal cancer : No impact on the pathologic complete response rate?]Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational databasePathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.[Neoadjuvant short-term radiotherapy followed by FOLFOX chemotherapy : No standard treatment for rectal cancer].Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis.Comparative Analysis of Efficacy, Toxicity, and Patient-Reported Outcomes in Rectal Cancer Patients Undergoing Preoperative 3D Conformal Radiotherapy or VMAT.Impact of Body Mass Index on Surgical and Oncological Outcomes in Laparoscopic Total Mesorectal Excision for Locally Advanced Rectal Cancer after Neoadjuvant 5-Fluorouracil-Based Chemoradiotherapy.Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study.The current status of treatment for colorectal cancer in China: A systematic review.
P2860
Q26738806-424C3420-92DE-469B-8B4D-4BA74B3DC825Q30235044-FED88249-0A34-433F-8350-38D27DE581E8Q33433227-2589367E-51C4-465F-9904-FCBAF8F5D798Q33776733-5C4C8900-FCAA-4FEE-AAC4-331089A750EFQ33798353-962394D8-3072-49E5-8E83-D96942D160E5Q33919715-09865A15-363B-4A3C-8785-BD23B1BD43D7Q35918934-4E0CA7DB-1AAF-4901-BC15-0BCC693993E1Q36056754-44275AB5-1131-4A04-BB78-1453DE48257CQ36303226-2D51C154-9CB6-4389-A161-BC584A170380Q36303649-56B3DD3D-28F9-4DB7-BB5D-263B6DAB7298Q36370649-5F9A04FA-D353-4213-8093-00A8D9A845A9Q36847230-DA9815ED-A9C1-4911-8BD5-F4B0114AA320Q37041204-22CB0B2A-08AF-4FF0-B466-EA7DE3F31B52Q37173767-56368064-1AEB-43EA-B3D4-BA9EE0FFC7CFQ37190135-646FCA8B-92A8-45F8-9523-9447F7B5A1F5Q37295422-F0A2ACC8-0396-4CB2-922E-BBC526CE6831Q37475229-28188A71-ED27-409A-B5C3-C04C650742AFQ37672022-C9583BA7-8A61-41F6-95DF-06BB0F1B6B48Q37686375-BC8AA2F9-B061-4913-86C1-965DB474BDBCQ37688901-9BF5891F-5CF7-44F2-92AB-E3A63B03A2AEQ37715201-6F538854-3B7F-4008-8E59-D71A85DFAD03Q38618772-6A71B218-3D8A-46E6-976C-BB0ED4C9ABD2Q38664897-2873B336-2832-41B9-A5DE-6583BF5AA8EEQ38692803-63432571-7A47-45E7-97F7-6F7590754FA1Q38734893-B2A7A169-E6EE-4008-8FAF-FB10AECE8658Q38767402-30C3C55F-D5D3-4DAE-83F1-D760713F1D26Q38850896-BECC4B59-CB5D-4B9A-9F2E-B06EC1E2F898Q39267610-8C5D9CC2-6736-4138-90E4-01B832AC12F1Q39268407-95109BBA-2038-433A-8EFE-BB74949CEEDEQ40427841-B08A8084-3B97-4C0D-898F-D920D1B304C6Q40447688-0103AF4F-0BF2-46C9-A402-AAEE97E3DB69Q40481695-0A539524-8DE6-4D79-A2FF-83A78E60FE99Q40531525-7F4FF474-94DA-430F-9C0C-1D94670578D9Q40531553-9A596FE6-1676-4FE2-B15C-15B9990F0051Q40970786-6AF4D884-D250-4016-83C4-A9F88BAC184CQ41696556-C92A03C0-3BC1-4CFE-A67A-C743878AC4C0Q42114982-1D3D4EE2-B194-47E7-BF2A-1D829F615C66Q43290671-DDF25272-ABDD-42AA-A655-68691C64A884Q43623679-6F1DB062-0C53-4661-9699-E2C631D09377Q47100034-D5A304D3-4E78-4B03-B829-ACBCA2FF464F
P2860
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Oxaliplatin added to fluoroura ...... el, randomised, phase 3 trial.
@en
type
label
Oxaliplatin added to fluoroura ...... el, randomised, phase 3 trial.
@en
prefLabel
Oxaliplatin added to fluoroura ...... el, randomised, phase 3 trial.
@en
P2093
P921
P1433
P1476
Oxaliplatin added to fluoroura ...... el, randomised, phase 3 trial.
@en
P2093
Anke Schlenska-Lange
Christian Wittekind
Dirk Arnold
Fritz Lindemann
Gerhard G Grabenbauer
German Rectal Cancer Study Group
Gunnar Folprecht
Hans Hoffmanns
Hans-Rudolf Raab
Hendrik A Wolff
P304
P356
10.1016/S1470-2045(15)00159-X
P577
2015-07-15T00:00:00Z